Tregs in ovarian cancer lesions suppress the immune response to tumor-associated antigens, which is achieved by suppressing the secretion of Interferon gamma (IFN-γ) and interleukin-2 (IL-2) by effector T cells. The gene discussed is IL2; the disease is ovarian cancer.